Crossmark

Fifteen-year trends in diabetes drug management and control in French-speaking Switzerland

Crossref DOI link: https://doi.org/10.1186/s13098-025-01620-z

Published Online: 2025-02-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pauli, Ariane https://orcid.org/0000-0001-6978-6900
Alkandari, Abdullah https://orcid.org/0000-0002-9452-7000
Marques-Vidal, Pedro https://orcid.org/0000-0002-4548-8500
Funding

Funding for this research was provided by:

University of Lausanne
License Information

Text and Data Mining valid from 2025-02-12

Version of Record valid from 2025-02-12
More Information

Article History

Received: 25 September 2024

Accepted: 29 January 2025

First Online: 12 February 2025

Declarations

:

: The institutional Ethics Committee of the University of Lausanne, which afterwards became the Ethics Commission of Canton Vaud () approved the baseline CoLaus study (reference 16/03, decisions of 13th January and 10th February 2003). The approval was renewed for the first (reference 33/09, decision of 23rd February 2009), the second (reference 26/14, decision of 11th March 2014) and the third (reference PB_2018-00040, decision of 20th March 2018) follow-ups. The approval for the entire CoLaus|PsyCoLaus study was confirmed in 2021 (reference PB_2018-00038, 239/09, decision of 21st June 2021). The full decisions of the CER-VD can be obtained from the authors upon request. The study was performed in agreement with the Helsinki declaration and its former amendments, and in accordance with the applicable Swiss legislation (LRH 810.30, approved by the Swiss Federal Parliament on 30th of September 2011). All participants gave their signed informed consent before entering the study.

: PMV reports support for attending meetings and/or travel by Pierre Fabre Pharma. The other authors report no conflict of interest.

Document is current

Any future updates will be listed below